Editas Medicine Inc (EDIT)

NASDAQ
Currency in USD
1.38
+0.15(+12.20%)
Closed
After Hours
1.37-0.01(-0.72%)
EDIT Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Unusual trading volume
Fair Value
Day's Range
1.241.48
52 wk Range
1.1211.58
Key Statistics
Edit
Prev. Close
1.38
Open
1.24
Day's Range
1.24-1.48
52 wk Range
1.12-11.58
Volume
8.95M
Average Volume (3m)
2.69M
1-Year Change
-83.07%
Book Value / Share
2.13
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
EDIT Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
3.75
Upside
+171.74%
Members' Sentiments
Bearish
Bullish
ProTips
5 analysts have revised their earnings upwards for the upcoming period
Show more

Editas Medicine Inc Company Profile

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Editas Medicine Inc SWOT Analysis


Strategic Pivot
Editas Medicine shifts focus to in vivo gene editing, restructuring operations and extending cash runway amid market challenges and pipeline changes
Financial Outlook
Analyst price targets range from $1 to $8, reflecting uncertainty. Cash reserves extended to Q2 2027, but profitability remains distant
Competitive Edge
Explore Editas' potential in liver and HSC editing, leveraging strong IP portfolio for partnerships in a less crowded market segment
Future Catalysts
Delve into Editas' long-term prospects in emerging in vivo gene editing field, balancing extended runway against pipeline uncertainties
Read full SWOT analysis

Compare EDIT to Peers and Sector

Metrics to compare
EDIT
Peers
Sector
Relationship
P/E Ratio
−0.5x−2.5x−0.7x
PEG Ratio
−0.12−0.100.00
Price/Book
0.6x1.1x2.6x
Price / LTM Sales
1.8x16.9x3.1x
Upside (Analyst Target)
153.6%677.8%47.6%
Fair Value Upside
Unlock31.1%7.7%Unlock

Analyst Ratings

4 Buy
9 Hold
2 Sell
Ratings:
15 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 3.75
(+171.74% Upside)

Earnings

Latest Release
-
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

People Also Watch

6.370
QBTS
-2.00%
1.850
PACB
+25.00%
34.64
DVN
+1.23%

FAQ

What Is the Editas Medicine (EDIT) Stock Price Today?

The Editas Medicine stock price today is 1.38

What Stock Exchange Does Editas Medicine Trade On?

Editas Medicine is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Editas Medicine?

The stock symbol for Editas Medicine is "EDIT."

What Is the Editas Medicine Market Cap?

As of today, Editas Medicine market cap is 113.92M.

What is Editas Medicine Earnings Per Share?

The Editas Medicine EPS is -2.56.

What Is the Next Editas Medicine Earnings Date?

Editas Medicine will release its next earnings report on 25 Feb 2025.

From a Technical Analysis Perspective, Is EDIT a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.